A novel bisphosphonate derivative (1-aminoethane-1,1-diyl)diphosphonic acid (AEDP) has been prepared and successfully labeled with 99m Tc at high labeling yields. The in vivo biodistribution of 99m Tc-AEDP has been investigated and compared with two reference compounds Tc-99m methylene diphosphonate ( 99m Tc-MDP) and Tc-99m (1-hydroxyethylidene) diphosphonate ( 99m Tc-HEDP). The biodistribution studies have demonstrated a high uptake of the radiotracer 99m Tc-AEDP in the bone and a rapid clearance from the blood (such as the two technetium-labeled bone imaging agents in current use: 99m Tc-MDP and 99m Tc-HEDP). Additionally, the scintigraphic images of 99m Tc-AEDP in normal rats have revealed high selective skeletal uptake.
Introduction
Technetium-99m radiopharmaceuticals play an important role in wide range of applications in nuclear medicine. Bone imaging agents are among the fi rst developed 99m Tc-radiopharmaceuticals and the most widely used radiopharmaceuticals in diagnostic nuclear medicine [1] . Bisphosphonates (BPs) are synthetic organic compounds characterized by a P-C-P backbone structure. They are chemically stable analogues of the endogenous metabolites, inorganic pyrophosphates. The biological effects of BPs on calcium metabolism were originally ascribed to their physicochemical effects to impede the dissolution of hydroxyapatite crystals [2] [3] [4] .
Because of their inhibitory effect on the bone resorption, various types of BPs are used in bone scanning, and provide an effective way of diagnosis of primary bone cancer, metastatic bone disease, Paget's disease, osteoporosis, bone trauma, etc. Several 99m Tc-labeled BPs have been synthesized, such as methylenediphosphonic acid (MDP) [2] , (1-hydroxyethane-1,1-diyl)diphosphonic acid (HEDP) and hydroxyl methylene diphosphonate (HMDP), (Fig. 1 ), and used in nuclear medicine for both diagnosis and treatment purposes [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
To continue the previous efforts to fi nd better bone-imaging agents, we report in this manuscript the synthesis of a new bisphosphonate compound, AEDP, and investigate its radiolabeling abilities with 99m Tc. Subsequently, we have performed preliminary in vivo studies in rats and compared the results with those obtained using two reference 
Materials and methods
All chemical reagents and solvents were of commercial quality and used as received. NMR spectra were acquired using a Bruker Bio spin 400 spectrometer (400 MHz for 1 H, 100 MHz for 13 C). Chemical shifts () were expressed in ppm relative to tetramethyl silane (TMS) as an internal standard. Melting point (MP) determination was performed using a digital melting point instrument from Stuart model SMP3. Infrared spectra were recorded as KBr pellets in the range 4000-400 cm −1 using an FTIR-JASCO 300E. ITLC (instant thin-layer chromatography) measurement was carried out using Whatman No. 3 strips (Sigma Chemical Company, USA) and radioactivity counted in a gamma scanner (Raytest mini GITA, Model BGO-V-detector) equipped with NaI(Tl) detector and single channel analyzer. MDP and HEDP kits were provided as commercial available kits produced by Atomic Energy Commission of Syria. Bone scan was performed with a gamma camera (Siemens Signature, Duel head, Damascus, Syria). Microanalysis was performed using a EURO EA analyzer. X-ray powder diffraction (XRD) patterns were obtained using a Stoe Stadi-P diffractometer with monochromatic Cu K 1 radiation ( = 1.5406 Å) selected using an incident-beam curved--crystal germanium Ge(111) monochromator, using the Stoe transmission geometry (horizontal set-up) with a linear position-sensitive detector (PSD).
Experimental

Synthesis of (1-aminoethane-1,1-diyl)diphosphonic acid (AEDP)
To a mixture of acetonitrile (150 ml), phosphorous acid (16.8 g, 0.2 mol) in glacial acetic acid (10 g, 0.167 mol) was added dropwise phosphoryltrichloride (51.7 g, 0.334 mol) at 55-65°C. The resulting mixture was stirred for 24 h at 70-75°C. The reaction mixture was cooled down to 60-65°C, and then water (150 ml) was added slowly. The reaction temperature was then increased to 90-100°C and maintained for the next 4-6 h. The reaction mixture was cooled down to 0-5°C and stirred for 3 h. The solid product was separated by fi ltration, washed with water, and fi nally, with methanol to produce the corresponding product, in 77% yield. 
Synthesis of (1-hydroxyethane-1,1-diyl)diphosphonic acid (HEDP)
A mixture of (5.13 g, 62.56 mmol) phosphorous acid and (7.74 g, 75.07 mmol) dried acetic anhydride was refl uxed for 4 h at 105°C (Scheme 2). At the same temperature, water vapor was bubbled through the mixture until the distillate became almost free of acid. The reaction mixture was concentrated in a rotary evaporator to yield crystals of HEDP monohydrate. The solid product was separated by fi ltration and washed with acetone to produce the corresponding product, in 90% yield, MP = 106.3-106.6°C.
Spectroscopic data of HEDP: 1 
Powder X-ray diffraction analysis of AEDP
The compound crystallizes as a fi ne white powder, therefore, a laboratory powder X-ray diffraction data was used for phase identifi cation. The powder X-ray diffraction data were collected at room temperature with a STOE transmission STADI-P diffractometer using Cu K 1 radiation ( = 1.54060 Å) selected with an incident-beam curved-crystal Ge(111) monochromator with a linear PSD. The pattern was scanned over the angular range 5.0-95.0° (2). For phase identifi cation, a Crystallography Open Database (COD) interfaced by the program QualX [15] was used. This program reports that the crystal structure of this compound was published by Tsaryk et al. [16] as a second triclinic polymorph of (1-ammonio-1-phosphonoethyl)phosphonate. Moreover, Rietveld analysis of the powder pattern for this compound (Fig. 2) indicates that the asymmetric unit of this compound, C 2 H 9 NO 6 P 2 , contains one molecule as a zwitterion. The N atom of the amino group is protonated and one of the phosphonic acid groups is deprotonated. Bond lengths and angles are similar to those obtained from single crystal data [16] . H atoms involved in these hydrogen bonds are located at inversion centers. These bonds and additional O-H...O and N-H...O hydrogen bonds interlink the molecules, giving a three-dimensional supramolecular structure (Fig. 3 ).
Preparation of kits
375 mg of AEDP or HEDP was dissolved in 15 ml double distilled water in a vial. 312 l of freshly prepared aqueous solution of SnCl 2 ·2H 2 O in nitrogen purged (400 mg SnCl 2 ·2H 2 O/0.5 ml concentrated HCl/5 ml H 2 O) was added into the vial. The pH was adjusted to 7.5 with sodium hydroxide solution. The fi nal solution was adjusted with water to 25 ml and the resulting solution was sterilized by fi ltration through a cellulose ester fi lter (0.22 m). Aliquots of 1 ml were transferred to glass vials and lyophilized for 24 h. The lyophilized vials were sealed under vacuum and stored in a refrigerator at 4°C.
Radiolabeling of AEDP, HEDP, and MDP with 99m Tc
Radiolabeling of the kit involves initial warming up of the vial to room temperature followed by the addition of 370-740 MBq (10-28 mCi) of freshly eluted 99m TcO 4in 2 ml of normal saline and fi nally, incubation of the vial for 15 min at room temperature. Radiochemical purity was determined by ITLC as follows: 5 l of the prepared compound was spotted on 10 cm Whatman No. 3 strips (Sigma Chemical Company, USA). The strips were then run with acetone and saline solution as mobile phases. After developing, the radioactivity was counted by a gamma scanner (Raytest mini GITA, Model: BGO-V-detector) equipped with NaI(Tl) detector and a single channel analyzer. By using acetone as the mobile phase, reduced 99m Tc and 99m Tc-complexes remained near the point of spotting with R f values <0.2, while free 99m TcO 4moved towards the solvent front. By using saline solution as another mobile phase, 99m Tc-complexes and 99m TcO 4moved towards the solvent front with R f values >0.9, whereas reduced 99m Tc remained at the point of spotting ( Figs. 4 and 5) . Fig. 3 . The molecular structure of (1-aminoethane-1,1--diyl)diphosphonic acid (AEDP) obtained by Rietveld refi nement. Fig. 4 . TLC pattern of 99m Tc-AEDP complex in acetone.
In vivo experiments
Experiments in rats were carried out in accordance with appropriate European Community directive guidelines (86/609/EEC). Biodistribution studies were performed in healthy Wister Han rats (male, 160-220 g). 0.3 ml of 99m Tc-AEDP, 99m Tc-HEDP or 99m Tc-MDP (2.2-3.7 MBq) in saline were administered to rats intravenously via the tail vein. The animals were anesthetized and sacrifi ced, routinely 1, 3, and 24 h post-intravenous injection (p.i.), and selected organs were taken out. The radioactivity of weighted samples of femur, heart, liver, lungs, kidneys, spleen, stomach, intestine, and blood were measured using a gamma counter CE/SN:03 L 504. The uptakes in the different selected organs, expressed as %ID(±SD)/g, of the organs for all the radiolabeled phosphonate complexes are given in Tables 1-3 . Bone-to-blood and bone-to-muscle uptake ratios were determined from the %ID/g values for the organs. Imaging studies were performed in normal rats (Wistar Han, male, 160-220 g) at 1 h after intravenous injection of 29.6 MBq (0.8 mCi) of 99m Tc-AEDP, 99m Tc-HEDP or 99m Tc-MDP, respectively.
Results and discussion
New product AEDP was synthesized according to the reaction scheme shown in Scheme 1. The synthesis was started with the addition of phosphoryltrichloride to a mixture of acetonitrile and phosphorous acid to obtain crude AEDP. The solid product was separated by fi ltration, then washed with water and methanol to give pure AEDP in 77% yield.
AEDP was characterized by 13 C, 31 P, 1 H-NMR, XRD, EA, and IR spectroscopic techniques. 1 H-NMR spectrum of AEDP showed a triplet peak representing the phosphorus splitting of the methyl hydrogens.
AEDP was labeled with 99m Tc in high labeling yields. Radiochemical purity and radiochemical yields were determined by ITLC and found to be greater than 97% (Fig. 4) .
Biodistribution of 99m Tc-AEDP was studied in rats and the results were compared with those obtained using 99m Tc-HEDP and 99m Tc-MDP. One hour post injection, 99m Tc-AEDP, 99m Tc-HEDP, and 99m Tc-MDP showed signifi cant uptake by bone. Femur was taken as a representative of the skeleton and observed uptakes in femur were 5.54%/g, 12.7%/g, and 4.67%/g for 99m Tc-AEDP, 99m Tc-HEDP, and 99m Tc-MDP, respectively, at 1 h post injection. No leaching of the activity from bone was observed for 99m Tc-MDP from 1 to 3 h post injection. In contrast, the activity of bone was decreased after 24 h post injection for 99m Tc-AEDP. Also, the activity of bone was decreased after 3 h for 99m Tc-HEDP. No increase of the uptake in any of the organs and tissues were observed with exception in stomach for 99m Tc-AEDP. The activities in blood were 1.38%/g, 3.65%/g, and 1.7%/g for 99m Tc-AEDP, 99m Tc-HEDP, and 99m Tc-MDP, respectively, at this time point and no signifi cant accumulation of the activity was observed in any of the major organs except in kidneys. However, the uptake observed in kidneys showed an increase up to 3 h, then decreased from 3 to 24 h for both 99m Tc-AEDP and 99m Tc-HEDP. In contrast, the uptake was decreased from 1 to 3 h, then increased from 3 to 24 h for 99m Tc-MDP. From 30 to 50% of the injected activity was cleared via urinary excretion within 3 h post injection for all the complexes. The bone-to-muscle uptake ratios of 99m Tc-AEDP were 167 and 242 at 3 and 24 h, respectively. While the bone-to-muscle uptake ratios of 99m Tc-HEDP and 99m Tc-MDP were 21.4, 367 and 95.6, 211 at 3 and 24 h, respectively, as given in Tables 1-3 . Scintigraphic images of 99m Tc-AEDP, in normal rats revealed highly selective skeletal uptake compared with both 99m Tc-HEDP and 99m Tc-MDP ( Fig. 6 ).
Conclusion
A new bisphosphonate analogue as ligand for bone study was developed and evaluated in rats. The labeling effi ciency of 99m Tc-AEDP, as determined by ITLC, was greater than 97%. Radioactivity in bone tissue was as high as 5.54 ± 0.98% ID/g (mean ± SD, n = 6) at 1 h after injection and decreased to 2.42 ± 0.31% ID/g at 24 h. Activity in kidneys was the highest at 3 h after injection. The radioactivities in muscle, stomach, small intestine, liver, and blood were all lower than 0.6% ID/g from 1 to 24 h.
The bone-to-blood uptake ratio was 4.01 at 1 h and increased to 9.8 at 3 h post injection, then decreased to 6.54 at 24 h. While, the bone-to-muscle uptake ratio increased from 138 at 1 h to 242 at 24 h. A major part of the injected radiotracer (~54%) was excreted by the urinary system by 3 h. In conclusion, 99m Tc-AEDP appears to be a good potential candidate for clinical use as a bone-seeking agent, since it displays highly selective uptake in the skeletal system, has low non-target uptake, and rapid clearance in blood. Scintigraphic images of 99m Tc-AEDP in normal rats revealed selective skeletal uptake.
